{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:47:20Z","timestamp":1774579640003,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T00:00:00Z","timestamp":1398729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We evaluated long\u2010term outcome of patients achieving complete response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>) after autologous stem cell transplantation (<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>) for multiple myeloma. Between April 1990 and June 2012 191 patients underwent <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>. The median age was 53\u00a0years (range, 26\u201368\u00a0years), 135 were men. Pretransplant, patients received induction therapy with <jats:styled-content style=\"fixed-case\">VAD<\/jats:styled-content> (vincristine, doxorubicin, dexamethasone; <jats:italic>n<\/jats:italic>\u00a0=\u00a077), novel agents (<jats:italic>n<\/jats:italic>\u00a0=\u00a092), or alkylating agent\u2010based, <jats:italic>n<\/jats:italic>\u00a0=\u00a022); 43% received more than one line of induction regimen. Response to transplant was defined as per <jats:styled-content style=\"fixed-case\">EBMT<\/jats:styled-content> criteria. The median follow\u2010up for the entire group was 85\u00a0months (range, 6\u2013232.5\u00a0months). Following transplant 109 (57.1%) patients achieved <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>. Median progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) for patients with <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> was higher compared to those with <jats:styled-content style=\"fixed-case\">VGPR<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>, (107 vs. 18 vs. 18\u00a0months, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). Number of lines of therapy pretransplant (one or two vs. more than two lines of therapy (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001), and absolute lymphocyte count of \u22643000\/cmm were predictors of superior <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>. Median overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) for patients with <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> was higher, (204\u00a0months), compared to those with <jats:styled-content style=\"fixed-case\">VGPR<\/jats:styled-content> (71.5\u00a0months, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) and <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> (51.5\u00a0months, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001), respectively. On Cox regression analysis, patients who received one line of induction therapy pretransplant (hazard ratio, <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 2.154, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) and those with absolute lymphocyte count of \u22643000\/mm<jats:sup>3<\/jats:sup> (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0.132, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) had superior <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>. For overall survival, induction treatment up to one line (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 2.403, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.004) and Hb\u00a0&gt;\u00a07.1\u00a0G\/dL at diagnosis (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 4.756, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01) were associated with superior outcome. On landmark analysis at 12\u00a0months, <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> continued to remain superior for patients attaining <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>. Achievement of <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> post transplant is associated with longer <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>. Among complete responders, those who receive one line of induction therapy pretransplant have superior outcome.<\/jats:p>","DOI":"10.1002\/cam4.257","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T05:50:43Z","timestamp":1398750643000},"page":"939-946","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Complete response after autologous stem cell transplant in multiple myeloma"],"prefix":"10.1002","volume":"3","author":[{"given":"Lalit","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Laboratory Oncology Institute Rotary Cancer Hospital All India Institute of Medical Sciences New Delhi 11 00 29 India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nida","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Laboratory Oncology Institute Rotary Cancer Hospital All India Institute of Medical Sciences New Delhi 11 00 29 India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Mookerjee","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Laboratory Oncology Institute Rotary Cancer Hospital All India Institute of Medical Sciences New Delhi 11 00 29 India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh Kumar","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Laboratory Oncology Institute Rotary Cancer Hospital All India Institute of Medical Sciences New Delhi 11 00 29 India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Om D.","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Laboratory Oncology Institute Rotary Cancer Hospital All India Institute of Medical Sciences New Delhi 11 00 29 India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Batra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Laboratory Oncology Institute Rotary Cancer Hospital All India Institute of Medical Sciences New Delhi 11 00 29 India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Pramanik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Laboratory Oncology Institute Rotary Cancer Hospital All India Institute of Medical Sciences New Delhi 11 00 29 India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Laboratory Oncology Institute Rotary Cancer Hospital All India Institute of Medical Sciences New Delhi 11 00 29 India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.09.010"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-238196"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-201053"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.9721"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11534"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-332320"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4250"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6081"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.051169"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.343"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.08.007"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-211953"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.176"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1060"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21804"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-307645"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.12.512"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma. Upfront or rescue treatment ? Results of a multicenter sequential randomized trial","volume":"92","author":"Fermand J. P.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-159624"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2119"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.217"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0527"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.257","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.257","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.257","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T12:30:04Z","timestamp":1695558604000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,29]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1002\/cam4.257"],"URL":"https:\/\/doi.org\/10.1002\/cam4.257","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,29]]},"assertion":[{"value":"2013-12-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}